Member Info for Bermudashorts

dodgepot - good for you and thanks for coming back to let us know BruceJamieson - Hardman reports make it crystal clear that the whole pipeline is pre-clinical I have no idea how this will turn out but it is not yet irreversible and am certain frantic discussions are taking place. It will be absolutely disgraceful if all the money ploughed into Redx is allowed to go to waste.

The Hardman Report issued in August 2016 had this to say about the Liverpool loan:- "£2.0m convertible loan with Liverpool City Council due to be repaid March 2017 or converts into shares subject to agreement of both parties" Can only think that Redx hoped they would allow the debt to be converted to shares but Liverpool Council were having none of it. http://www.hardmanandco.com/docs/default-source/company-docs/redx-pharma--documents/08-08-16--advancing-to-clinic-increasing-value

Of course, the fact remains that the Company took a loan from Liverpool City Council 5 years ago. Presumably the Council offered the loan to help create new jobs for Liverpool. Not only did Redx fail to meet the repayment deadline, but to add insult to injury they moved all jobs from Liverpool to Alderley Edge. They have already been given an extra 2 years to repay the loan and despite the funding earlier in the year the situation has been allowed to come to this. A pretty sorry state of affairs really. Just to reiterate an earlier point - this Company has been given over £10 million in regional grant funding - the UK bio industry is full of small companies who are desperate for cash. It will be absolutely disgraceful if this cash is wasted.

This from Liverpool's Mayor, Joe Anderson:- "Even at the 11th hour the city council was willing to work on a repayment schedule but it is now clear Redx has no intention to work with us in any meaningful way" This from Redx Chariman, Ian Ross:- "The timing of this action by LCC and its advisers FRP is extremely unfortunate and quite baffling considering our efforts to have face-to-face discussions, including earlier today, the immediate offer of a payment plan and our latest proposal to make an immediate £1m payment in return for a short grace period."

Having loaned the Company £2m, I don't suppose Liverpool Council were thrilled with the announcement of the move to Alderley Park last year "The Redx Pharma move will be completed by year-end and see all 193 Redx staff operate on the same site for the first time, with all 88 Liverpool-based job roles relocating." Nevertheless, it's hard to see how forcing the Company into administration can be the best way to ensure the people of Liverpool to get their money back. Hope for all concerned that logic prevails and they somehow manage to resolve this issue. REDX have received millions and millions in grant funding - most of it Regional Growth Fund money. They have a very promising pipeline and are a high profile representative of the UK bio industry. What a shame and a complete and utter waste for all concerned if this can't be turned around. http://redxpharma.com/news/2016/2016.04.14.html?filter=

Temporary suspension of trading pending an announcement:- http://www.investegate.co.uk/aim/redx/suspension---redx-pharma-plc/201705241635021544G/?fe=1&utm_source=FE%20Investegate%20Alerts&utm_medium=Email&utm_content=Announcement%20Alert%20Mail&utm_campaign=AIM%20Alert Perhaps in connection with the ongoing dispute with Liverpool City Council re. investment loan?

"The plan is to submit our package to the FDA by the end of 2017 … for a platform authorization." Newland said. "The Intended use of the system is to harvest CTCS from the blood of metastatic breast cancer for subsequent analysis … and the multiple downstream analyses — things like qPCR, NGS, FISH, immunostaining — those are the secondary endpoints," he said. Though the company hasn't announced other participating research centers yet, Newland said that the study will involve six in total." https://www.genomeweb.com/sample-prep/angle-working-toward-fda-approval-ctc-isolation-platform-breast-cancer-testing

Good interview here with CEO. Pipeline sounds very promising and the second porcupine inhibitor for fibrotic diseases sounds particularly interesting. Of course the big question is how they are going to fund development of the pipeline as it moves through the clinic. http://www.proactiveinvestors.co.uk/companies/stocktube/7474/redx-pharma-in-a-very-good-place-with-great-assets-ceo-neil-murray-7474.html

Bruce, this isn't a pharma it's an early stage, non revenue generating bio. It doesn't even yet have any products in the clinic. Whether they do the selling themselves is irrelevant - they have nothing to sell! You can't compare an AIM listed baby bio to pharma - they're completely different beasts and completely different investment propositions.

The abstracts have now been published for the ASCO Annual Meeting which will be held in Chicago in early June. MD Anderson have submitted an abstract detailing their research using the Parsortix system to try and identify a new biomarker for predicting resistance to anti-EGFR treatments. The conclusion from the abstract:- "We have successfully isolated CTCs from mCRC pts’ blood using Parsortix system. Elevated levels of arginine methylated EGFR is associated with a shorter PFS with anti-EGFR-based Rx. Assessment of meEGFR-CTCs may provide a “liquid biopsy” biomarker for reduced efficacy from anti-EGFR Rx." So the no. 1 cancer centre in the US is presenting research at ASCO highlighting the potential for the use of the Parsortix system to predict those less likely to benefit from EGFR inhibitors. So much positive stuff going on in the background here. http://abstracts.asco.org/199/AbstView_199_185418.html

Need to check but think the poster said end of 2017 for IND submission to FDA

Link to poster can be found at top right here:- http://redxpharma.com/investors/ Looks like Redx have achieved some pretty impressive preclinical results in comparison to Ibrutinib - let's hope they are replicated in the clinic.

Good to see some activity here - well at least as far as the SP is concerned!

Excellent update this morning. Ovarian cancer studies recruitment complete and on track to report top line results this quarter Breast cancer studies for FDA clearance on track for completion in 2017 No. of Parsortix systems installed increased from 85 to 145 over the past year Revenues from cassette sales up 500% Cash of £5.5 million with R&D tax credit due The fact that M D Anderson are leading the breast cancer study (for FDA approval) is very interesting - the No. 1 ranked cancer hospital in the US with an outstanding, world-class reputation for cancer research. James Allison is professor and Chair of Immunology at M D Anderson. He is largely credited with the current immunotherapy revolution in cancer treatment and is responsible for the discovery and development of checkpoint inhibitors. Really good news and very impressive that such an institution will be leading such an important study for Angle. http://www.investegate.co.uk/angle-plc--agl-/rns/business-update/201705030700119768D/

Just found your bottle:) The short answer is that I have no idea - have looked hard for articles with any sort of informed opinion and come up with very little. AUM of £745m at last financial Y/E, predicted (largely thanks to Odgen rate change) to grow to over £1 billion next year and importantly 99% client retention for the last 8 years. Given their expertise in the structured settlements field, it's hard to imagine that there wouldn't be significant interest in the Company. Worth having a quick scan of the 8.3 forms - BOD hold over 21% of shares and some interesting names amongst the other holders. No doubt all will be looking for a handsome return. I believe the schedule is that they will invite formal proposals during May so hopefully we should find out more in the not too distant future.

Wow! Excellent RNS- using CRISPR gene editing to correct the faulty gene in sickle cell disease and at the same time tackling DNA mutations. "Using MaxCyte's Proprietary GT® System, MaxCyte and its collaborators at the National Heart, Lung and Blood Institute (NHLBI) and National Institute of Allergy and Infectious Diseases (NIAID) demonstrated successful CRISPR-induced corrections of the mutation behind SCD in more than 30 percent of patient-derived B cells" Technology is in its infancy but the potential in a whole range of conditions is mind boggling. http://www.investegate.co.uk/maxcyte--inc---mxct-/rns/presentation-of-positive-preclinical-data/201704250700121821D/

N+1 Singer have increased their target for Ergomed from 293 to 360. Zoptrex phase III results due from Aeterna Zentaris any day now.

"Ergomed, a profitable UK-based group dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, announces that on 3 April 2017, Mr Peter George, Chairman of the Company, bought 100,000 ordinary shares of 1p each in the Company ("Share(s)") at a price of 190p per Share." http://www.investegate.co.uk/ergomed-plc--ergo-/rns/director-pdmr-shareholding/201704041050015275B/

Really encouraging RNS. The current line of thinking is that both Merck's Keytruda and BMS' Opdivo anti PD-1 immunotherapy treatments produce a greater response rates in patients with tumours expressing high levels of PD-L1. There are several other checkpoint inhibitors in development falling into this category too. So this is great news. "The results show that in a study of 40 cancer patients, the Parsortix system demonstrated higher sensitivity and greater purity in harvesting CTCs for analysis than leading alternative approaches. Information regarding the expression of key genes (including PD-L1 and CK-19) could be determined from simple blood samples taken from each patient. In parallel, identical samples from each patient were assessed using antibody-based (EpCAM-dependent) approaches. These approaches failed to detect PD-L1 or CK-19 in any of the 40 samples."

"As part of the Board's strategic review of how to maximise the Group's potential to capture fully the substantial market opportunity and to enhance shareholder value, a formal sale process is being commenced, in accordance with Note 2 on Rule 2.6 of The City Code on Takeovers and Mergers (the "Code")" http://www.investegate.co.uk/frenkel-topping-grp/fen/strategic-review-and-formal-sale-process/201704030700092727B/?fe=1&utm_source=FE%20Investegate%20Alerts&utm_medium=Email&utm_content=Announcement%20Alert%20Mail&utm_campaign=Frenkel Topping Grp%20Alert